MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

Core Viewpoint - The securities class action lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made materially false and misleading statements about the clinical prospects of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Company Overview - MoonLake Immunotherapeutics is facing a class action lawsuit due to claims regarding the efficacy of its drug candidate, sonelokimab (SLK), which is based on a unique Nanobody structure [3][4]. - The company’s stock price fell from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and showed inferior efficacy compared to a competitor [4]. Legal Context - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [4][5]. - Hagens Berman, the law firm leading the litigation, is encouraging investors who suffered significant losses during this period to come forward and discuss their legal options [5][6]. Investor Actions - Investors who purchased MoonLake stock within the specified class period and experienced substantial losses are urged to contact Hagens Berman to explore potential legal recourse and the possibility of being appointed as Lead Plaintiff [5][6].